| Drug Name |
Apixaban |
| Drug ID |
BADD_D00151 |
| Description |
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043]. |
| Indications and Usage |
Apixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures. |
| Marketing Status |
Prescription |
| ATC Code |
B01AF02 |
| DrugBank ID |
DB06605
|
| KEGG ID |
D03213
|
| MeSH ID |
C522181
|
| PubChem ID |
10182969
|
| TTD Drug ID |
D0I5HF
|
| NDC Product Code |
0003-0893; 65129-1344; 55111-980; 50193-0893; 63629-8432; 16436-0113; 70366-001; 46708-908; 52048-0420; 63850-8085; 42816-0893; 14445-150; 59651-051; 53747-062; 65015-897; 55154-0613; 66174-0091; 76397-007; 75945-060; 24196-190; 15308-1221; 12783-0894; 66651-921; 63415-0520; 70518-1861; 66039-925; 65372-1196; 55154-0612; 12783-0893; 69989-0006; 76397-010; 42765-025; 76072-1017; 14501-0089; 67835-0015; 69037-0023; 50090-1437; 0003-0894; 58623-0137; 0003-3764; 42816-0894; 67296-1673; 58032-2028; 50090-1436; 65727-081; 14445-014; 63629-7747; 14445-149 |
| Synonyms |
apixaban | Eliquis | BMS 562247 | BMS562247 | BMS-562247-01 | BMS-562247 |
